Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Short term Debt (2023 - 2024)

TScan Therapeutics (TCRX) has disclosed Short term Debt for 2 consecutive years, with $10.3 million as the latest value for Q2 2024.

  • On a quarterly basis, Short term Debt changed N/A to $10.3 million in Q2 2024 year-over-year; TTM through Jun 2024 was $10.3 million, a N/A change, with the full-year FY2023 number at $3.3 million, changed N/A from a year prior.
  • Short term Debt was $10.3 million for Q2 2024 at TScan Therapeutics, up from $6.8 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $10.3 million in Q2 2024 to a low of $1.1 million in Q3 2023.